DOCSLIB.ORG

ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update) ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Afghanistan Oxycodone 43 000 Codeine 50 000 Oxymorphone 300 Dextropropoxyphene 2 000 000 Pethidine 65 000 Diphenoxylate 20 000 Remifentanil 9 100 Fentanyl 6 Sufentanil 1 Methadone 6 000 Thebaine 45 000 Morphine 4 000 Armenia Pethidine 80 000 Codeine 3 000 Pholcodine 100 000 Fentanyl 21 Albania Methadone 10 000 Codeine 35 000 Morphine 4 500 Fentanyl 40 Thebaine 10 Methadone 9 000 Trimeperidine 650 Morphine 3 000 Aruba* Pethidine 2 500 Alfentanil 3 Pholcodine 1 000 Bezitramide 1 Remifentanil 8 Cocaine 70 Sufentanil 1 Codeine 85 Algeria Dextromoramide 1 Alfentanil 500 Dextropropoxyphene 85 Codeine 1 000 000 Fentanyl 130 Etorphine 1 Hydrocodone 2 Fentanyl 1 000 Methadone 150 Morphine 11 000 Morphine 340 Pethidine 3 000 Opium 450 Pholcodine 2 500 000 Oxycodone 26 Sufentanil 30 Pethidine 404 Andorra Piritramide 20 Fentanyl 80 Remifentanil 19 Methadone 1 000 Ascension Island Morphine 500 Alfentanil 1 Oxycodone 1 500 Fentanyl 1 Pethidine 500 Morphine 2 Remifentanil 4 Pethidine 9 Angola* Australia Alfentanil 2 Alfentanil 400 Codeine 30 000 Cannabis 21 500 Dextromoramide 375 Cocaine 20 000 Dihydrocodeine 375 Codeine 9 800 000 Fentanyl 45 Conc. of poppy straw Morphine 11 000 AOA 4 000 000 Pethidine 13 000 ATA 85 000 000 Sufentanil 2 Dextromoramide 10 Anguilla Dextropropoxyphene 1 925 000 Fentanyl 1 Difenoxin 7 Morphine 20 Dihydrocodeine 285 000 Pethidine 300 Diphenoxylate 80 000 Antigua and Barbuda* Ethylmorphine 10 Cocaine 9 Etorphine 2 Codeine 169 Fentanyl 40 000 Dihydrocodeine 15 Heroin 10 Diphenoxylate 28 Hydrocodone 25 Fentanyl 1 Hydromorphone 60 000 Morphine 6 Levomethorphan 1 Oxycodone 2 Methadone 1 000 000 Pethidine 338 Morphine 1 210 000 Remifentanil 1 Norcodeine 1 Sufentanil 1 Normethadone 10 Argentina Opium 5 Anileridine 10 Oxycodone 2 200 000 Cannabis 50 Oxymorphone 10 Cannabis resin 20 Pethidine 120 000 Coca leaf 250 Pholcodine 1 550 000 Cocaine 120 Remifentanil 350 Codeine 88 000 Sufentanil 5 Dextromoramide 10 Thebaine 1 000 Dextropropoxyphene 2 400 000 Austria Dihydrocodeine 10 Alfentanil 400 Diphenoxylate 10 Cannabis 55 000 Ethylmorphine 22 000 Cocaine 2 000 Fentanyl 23 000 Codeine 500 000 Heroin 100 Codeine-N-oxide 50 Hydrocodone 18 000 Dextropropoxyphene 200 Hydromorphone 6 000 Dihydrocodeine 650 000 Levorphanol 10 Diphenoxylate 40 Methadone 80 000 Ethylmorphine 100 Morphine 709 000 Etorphine 4 Opium 50 000 Fentanyl 50 000 Oripavine 10 Heroin 4 - 1 - ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Hydrocodone 10 Methadone 33 000 Hydromorphone 130 000 Morphine 14 000 Methadone 100 000 Norcodeine 1 Morphine 2 200 000 Normorphine 1 Morphine-N-oxide 15 Oxycodone 1 Nicomorphine 2 000 Oxymorphone 1 Opium 11 000 Pethidine 1 Oxycodone 250 000 Remifentanil 1 Pethidine 20 000 Sufentanil 2 Piritramide 22 000 Thebaine 1 Remifentanil 4 500 Trimeperidine 50 000 Sufentanil 600 Belgium Thebaine 10 Acetyldihydrocodeine 2 000 Tilidine 10 Alfentanil 100 000 Azerbaijan Bezitramide 100 Codeine 2 000 Cannabis 20 000 Fentanyl 15 Coca leaf 2 000 Methadone 6 000 Cocaine 120 000 Morphine 700 Codeine 4 700 000 Trimeperidine 1 600 Dextromoramide 50 Bahamas Dextropropoxyphene 50 000 Cannabis 4 Difenoxin 10 Cannabis resin 4 Dihydrocodeine 482 000 Cocaine 4 Diphenoxylate 4 000 Codeine 2 000 Dipipanone 100 Dextropropoxyphene 2 800 Ethylmorphine 320 000 Fentanyl 1 Etorphine 50 Heroin 1 Fentanyl 1 000 000 Hydrocodone 1 Heroin 30 000 Hydromorphone 150 Hydrocodone 410 000 Morphine 800 Hydromorphone 40 000 Opium 4 Ketobemidone 50 Oxycodone 1 300 Levorphanol 10 Pethidine 8 000 Methadone 400 000 Sufentanil 1 Morphine 5 200 000 Thebaine 1 Nicomorphine 10 Bahrain Normethadone 10 Alfentanil 1 Opium 100 000 Codeine 1 000 Oripavine 50 Etorphine 3 Oxycodone 100 000 Fentanyl 100 Pethidine 50 000 Methadone 100 Phenoperidine 10 Morphine 6 000 Pholcodine 230 000 Oxycodone 200 Piritramide 1 000 000 Pethidine 15 000 Remifentanil 30 000 Remifentanil 100 Sufentanil 3 000 Bangladesh Thebacon 45 000 Dextropropoxyphene 450 000 Thebaine 10 Fentanyl 800 Tilidine 25 000 000 Methadone 15 000 Belize Morphine 100 000 Cocaine 100 Oxymorphone 25 000 Codeine 10 000 Pethidine 420 000 Dextropropoxyphene 4 000 Barbados Dihydrocodeine 50 Cocaine 178 Diphenoxylate 50 Codeine 124 080 Fentanyl 1 Dihydrocodeine 900 Hydrocodone 100 Fentanyl 11 Hydromorphone 100 Heroin 1 Methadone 1 000 Hydromorphone 3 Morphine 4 000 Methadone 765 Oxycodone 250 Morphine 2 228 Pethidine 4 200 Oxycodone 118 Benin Pethidine 9 424 Codeine 2 000 Remifentanil 125 Fentanyl 200 Sufentanil 1 Morphine 1 000 Belarus Pethidine 5 000 Alphaprodine 1 Remifentanil 10 Cocaine 100 Sufentanil 1 Codeine 3 000 000 Bermuda Dextromoramide 1 Alfentanil 10 Dextropropoxyphene 1 000 Cannabis 2 Dipipanone 1 Cannabis resin 1 Ecgonine 1 Cocaine 150 Ethylmorphine 500 Codeine 5 000 Etorphine 1 Dextromoramide 15 Fentanyl 1 500 Dextropropoxyphene 1 Heroin 1 Dihydrocodeine 2 000 Hydromorphone 2 500 Diphenoxylate 150 - 2 - ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Dipipanone 1 Opium 150 000 Etorphine 5 Oripavine 1 Fentanyl 60 Oxycodone 38 000 Heroin 1 Oxycodone-N-oxide 2 Hydrocodone 15 Oxymorphone 2 001 Hydromorphone 150 Pethidine 300 000 Methadone 4 000 Phenoperidine 1 Morphine 1 500 Pholcodine 1 Oxycodone 600 Piritramide 1 Oxymorphone 1 Remifentanil 3 000 Pethidine 3 000 Sufentanil 45 Pholcodine 100 Thebacon 1 Remifentanil 20 Thebaine 1 Bhutan Tilidine 1 Codeine 696 British Virgin Islands Etorphine 1 Codeine 84 Fentanyl 6 Dihydrocodeine 90 Morphine 511 Diphenoxylate 15 Pethidine 1 640 Fentanyl 3 Bolivia (Plurinational State of) Morphine 90 Codeine 353 480 Pethidine 750 Dextropropoxyphene 360 000 Brunei Darussalam Fentanyl 92 Cocaine 1 Methadone 900 Codeine 5 000 Morphine 6 570 Dihydrocodeine 1 000 Oxycodone 6 678 Ecgonine 2 Pethidine 14 790 Fentanyl 15 Remifentanil 19 Heroin 1 Bosnia and Herzegovina Hydromorphone 1 Alfentanil 30 Methadone 1 Cannabis 4 Morphine 1 200 Cannabis Oil 2 Pethidine 1 200 Cannabis resin 4 Pholcodine 500 Cocaine 2 Remifentanil 3 Codeine 78 000 Bulgaria Fentanyl 1 200 Alfentanil 30 Heroin 2 Cannabis 3 000 Methadone 30 000 Cocaine 1 Morphine 8 000 Codeine 4 000 000 Pethidine 500 Codeine-N-oxide 2 Pholcodine 24 000 Dextromoramide 1 Remifentanil 30 Dextropropoxyphene 500 Sufentanil 5 Dihydrocodeine 40 000 Botswana Ecgonine 2 Alfentanil 9 Ethylmorphine 15 000 Codeine 15 772 Fentanyl 600 Dihydrocodeine 2 669 Heroin 1 Etorphine 25 Hydromorphone 1 Fentanyl 21 Isomethadone 5 Morphine 10 625 Methadone 150 000 Pethidine 40 591 Morphine 90 000 Sufentanil 3 Morphine-N-oxide 2 Tilidine 300 Normorphine 1 Brazil Opium 10 Alfentanil 1 700 Oxycodone 30 000 Alphaprodine 1 Oxymorphone 1 Anileridine 1 Pethidine 25 000 Bezitramide 1 Piritramide 1 000 Cocaine 3 Remifentanil 25 Codeine 3 600 001 Sufentanil 20 Codeine-N-oxide 1 Tilidine 40 000 Dextromoramide 1 Burkina Faso Dextropropoxyphene 10 001 Alfentanil 1 Difenoxin 1 Fentanyl 6 Dihydrocodeine 1 Morphine 250 Diphenoxylate 1 000 Remifentanil 1 Dipipanone 1 Sufentanil 1 Ethylmorphine 1 Burundi* Etorphine 1 Codeine 1 000 Fentanyl 6 000 Fentanyl 139 Heroin 1 Morphine 1 000 Hydrocodone 1 Pethidine 6 500 Hydromorphone 12 000 Cambodia Ketobemidone 1 Codeine 205 000 Levorphanol 1 Dextropropoxyphene 300 000 Methadone 60 000 Fentanyl 6 Morphine 1 200 000 Methadone 6 000 Nicomorphine 1 Morphine 3 000 Normethadone 1 Pethidine 500 - 3 - ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Cameroon Morphine 10 000 Codeine 20 000 Pethidine 10 000 Fentanyl 2 Chile Morphine 11 000 Alfentanil 12 Pethidine 11 000 Codeine 805 540 Canada Ethylmorphine 3 500 3-Methyl thiofentanyl 10 Fentanyl 3 600 3-Methylfentanyl 2 Methadone 17 000 Alfentanil 400 Morphine 270 000 Alpha-methylfentanyl 5 Oxycodone 6 800 Alpha-methylthiofentanyl 5 Pethidine 30 000 Alphaprodine 100 Remifentanil 340 Anileridine 100 Sufentanil 1 Beta-hydroxyfentanyl 1 China Coca leaf 100 Alfentanil 1 Cocaine 20 000 Cannabis 5 Codeine 29 231 000 Cocaine 8 000 Dextropropoxyphene 1 500 000 Codeine 10 400 000 Difenoxin 15 Conc. of poppy straw Dihydrocodeine 200 AMA 21 030 000 Diphenoxylate 50 500 ATA 180 000 Dipipanone 60 Dihydrocodeine 450 000 Ethylmorphine 2 Diphenoxylate 3 200 000 Etorphine 10 Ethylmorphine 1 500 Fentanyl 150 000 Fentanyl 25 000 Heroin 3 000 Hydrocodone 20 000 Hydrocodone 110 000 Hydromorphone 5 000 Hydromorphone 1 500 000 Methadone 4 300 000 Isomethadone 600 Morphine 10 400 000 Ketobemidone 35 Opium 12 150 000 Levomethorphan 10 Oxycodone 600 000 Levomoramide 50 Pethidine 3 000 000 Levorphanol 105 Pholcodine 610 000 Methadone 2 500 000 Remifentanil 15 000 Moramide intermediate 50 Sufentanil 3 000 Morphine 4 000 000 Thebaine 650 000 Normethadone 20 000 Tilidine 30 000 Opium 20 000 Hong Kong Special Administrative Region of Oripavine 500 China Oxycodone 10 000 000 Alfentanil 20 Oxymorphone 100 000 Alphacetylmethadol 1 Pethidine 1 300 000 Anileridine 1 Piritramide 6 Cannabis 4 Racemoramide 50 Cannabis resin 2 Remifentanil 500 Coca leaf 2 Sufentanil 240 Cocaine 7 500 Thebaine 100 Codeine 4 501 000 Thiofentanyl 11 Desomorphine 1 Tilidine 16 Dextromoramide 5 Cape Verde* Dextropropoxyphene 1 000 Alfentanil 1 Dihydrocodeine 6 001 Codeine 700 Diphenoxylate 12 020 Fentanyl 8 Dipipanone 500 Methadone 8 Ecgonine 2 Morphine 400 Ethylmorphine 30 020 Pethidine 2 000 Etonitazene 1 Cayman Islands Etorphine 4 Alfentanil 1 Fentanyl 250 Cannabis 3 Heroin 15 Cocaine 20 Hydrocodone 150 Codeine 25 Hydromorphone 2 000 Dihydrocodeine 50 Levomethorphan 1 Fentanyl 48 Levorphanol
Load more

Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • Orphenadrine Hydrochloride 50Mg/5Ml Oral Solution Rare (Affect More Than 1 in 10,000 People) N Forgetting Things More Than Usual
    Uncommon (affect more than 1 in 1000 people) n Constipation Package Leaflet: Information for the user n Greater sensitivity to things around you or feeling nervous n Feeling light-headed and an unusual feeling of excitement (elation) n Difficulty sleeping or feeling tired. Orphenadrine Hydrochloride 50mg/5ml Oral Solution Rare (affect more than 1 in 10,000 people) n Forgetting things more than usual. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Reporting of side effects n Keep this leaflet. You may need to read it again. If you get any side effects, talk to your doctor, n If you have any further questions, ask your doctor pharmacist or nurse. This includes any possible side or pharmacist. effects not listed in this leaflet. You can also report n This medicine has been prescribed for you only. side effects directly (see details below). By reporting Do not pass it on to others. It may harm them, even side effects you can help provide more information on if their signs of illness are the same as yours. the safety of this medicine. n If you get any side effects, talk to your doctor or United Kingdom pharmacist. This includes any possible side effects not listed in this Yellow Card Scheme leaflet. See section 4. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or What is in this leaflet: Apple App Store. 1. What Orphenadrine Hydrochloride Oral Solution is and what is it used for 2.
    [Show full text]
  • Federal Register/Vol. 85, No. 36/Monday, February 24, 2020
    10466 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Controlled substance Drug code Schedule Alphamethadol ................................................................................................................................................................. 9605 I Benzethidine .................................................................................................................................................................... 9606 I Betacetylmethadol ........................................................................................................................................................... 9607 I Clonitazene ...................................................................................................................................................................... 9612 I Diampromide ................................................................................................................................................................... 9615 I Diethylthiambutene .......................................................................................................................................................... 9616 I Dimethylthiambutene ....................................................................................................................................................... 9619 I Ketobemidone .................................................................................................................................................................
    [Show full text]
  • Risk Based Requirements for Medicines Handling
    Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14.
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • Best Bets from the Manchester Royal Infirmary Edited by K Mackway-Jones
    247 BEST EVIDENCE TOPIC REPORTS Emerg Med J: first published as 10.1136/emj.19.3.248 on 1 May 2002. Downloaded from Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary Edited by K Mackway-Jones Clinical scenario Best evidence topic reports (BETs) summarise the evidence A 23 year old woman attends an emergency department hav- pertaining to particular clinical questions. They are not ing taken sixty 500 mg paracetamol tablets. Her four hour systematic reviews, but rather contain the best (highest paracetamol levels are above the treatment line. She does not level) evidence that can be practically obtained by busy want to be treated with intravenous therapy. You wonder practising clinicians. The search strategies used to find the whether oral antidote is as effective. best evidence are reported in detail in order to allow clinicians to update searches whenever necessary. The BETs published below were first reported at the Critical Three part question Appraisal Journal Club at the Manchester Royal Infirmary.1 In [patients who need an antidote for paracetamol overdose] Each BET has been constructed in the four stages that have is [intravenous therapy better than oral therapy] at [prevent- been described elsewhere.2 The BETs shown here together ing liver damage and death]? with those published previously and those currently under construction can be seen at http://www.bestbets.org.3 Six Search strategy BETs are included in this issue of the journal. Medline 1966 to 12/01 using the OVID interface. [exp acetyl-
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • LAAM in the Treatment of Opiate Addiction: Treatment Improvement Protocol (TIP) Series 22
    TIP 22: LAAM in the Treatment of Opiate Addiction: Treatment Improvement Protocol (TIP) Series 22 A43664 Ira J. Marion, M.A. Consensus Panel Chair U.S. Department of Health and Human Services Public Health Service Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment Rockwall II, 5600 Fishers Lane Rockville, MD 20857 DHHS Publication No. (SMA) 95-3052 Printed 1995. Disclaimer This publication is part of the Substance Abuse Prevention and Treatment Block Grant technical assistance program. All material appearing in this volume except quoted passages from copyrighted sources is in the public domain and may be reproduced or copied without permission from the Center for Substance Abuse Treatment (CSAT) or the authors. Citation of the source is appreciated. This publication was written under contract number ADM 270-91-0007 from the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration (SAMHSA). Sandra Clunies, M.S., served as the CSAT Government project officer. Robert A. Lubran, M.S., M.P.A., was the Government content advisor. Carolyn Davis, Constance Gartner, Linda Harteker, Lise Markl, Barbara Shapiro, and Deborah Shuman served as writers. The opinions expressed herein are the views of the consensus panel members and do not reflect the official position of CSAT or any other part of the U. S. Department of Health and Human Services (DHHS). No official support or endorsement of CSAT or DHHS for these opinions or for particular instruments or software that may be described in this document is intended or should be inferred. The guidelines proffered in this document should not be considered as substitutes for individualized patient care and treatment decisions.
    [Show full text]
  • Picquestion of the Week:1/09/12
    Grand Teton, Wyoming USA PIC QUESTION OF THE WEEK: 1/09/12 Q: Can fentanyl be prescribed for a patient allergic to codeine? A: Opioid analgesics are among the most commonly prescribed drugs in the United States. True allergic reactions to opioid analgesics are extremely rare, dependent upon antibody (usually IgE/IgG), and triggered by histamine and other mediators. Immediate reactions (e.g. anaphylaxis) are associated with contraction of smooth muscle, vasodilation, increased mucous secretion, and enhanced vasopermeability. More frequently, opioids such as morphine and codeine cause direct release of histamine from mast cells. These reactions are considered idiosyncratic, independent of antibody, and based on individual patient susceptibility. Direct release of histamine is the most common mechanism for the development of urticaria, pruritus, etc. in patients receiving natural opioids such as morphine and codeine. Opioid analgesics are typically classified according to the source of the chemical or the presence of structurally related groups (see table). In general, the risk of cross-reactivity is thought to be less likely among agents from a different source or structural class. If a reaction to morphine or codeine is severe in nature, substituting a synthetic or semi-synthetic agent or a structurally dissimilar compound appears to reduce the risk of cross-reactivity. It should be noted that although tramadol is classified as a synthetic opioid derivative, there have been cases of severe hypersensitivity reactions associated with its use. These cases have occurred in patients with and without a history of allergic reactions to opiates. Thus tramadol would probably not a good first alternative in a patient with a history of a severe reaction to this group of drugs.
    [Show full text]